A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

Part of paid clinical trials in Glendale, California.

Sponsor
AstraZeneca
Study ID
NCT07723833
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Elecoglipron Reference Formulation Dose A — DRUG
    Elecoglipron tablets will be administered orally.
  • Elecoglipron Test formulation 1 Dose A — DRUG
    Elecoglipron tablets will be administered orally.
  • Elecoglipron Reference Formulation Dose B — DRUG
    Elecoglipron tablets will be administered orally.
  • Elecoglipron Test formulation 1 Dose B — DRUG
    Elecoglipron tablets will be administered orally.
  • Elecoglipron Test formulation 2 Dose A — DRUG
    Elecoglipron tablets will be administered orally.
  • Elecoglipron Test formulation 2 Dose B — DRUG
    Elecoglipron tablets will be administered orally.

Study Details

The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.

Key Dates

First listed
Jul 23, 2026
Start date
Jul 27, 2026
Status verified
Aug 2026
Primary completion
Nov 18, 2026
Completion
Nov 18, 2026

Study Design

Enrollment
152 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1-Treatment Sequence A
    Participant will receive a single dose of elecoglipron reference formulation (Dose A) in Period 1 followed by a single dose of elecoglipron test formulation 1 (Dose A) in Period 2.
  • Experimental: Cohort 1 - Treatment Sequence B
    Participant will receive a single dose of elecoglipron test formulation 1 (Dose A) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose A) in Period 2.
  • Experimental: Cohort 2 - Treatment Sequence C
    Participant will receive a single dose of elecoglipron reference formulation (Dose B) in Period 1 followed by a single dose of elecoglipron test formulation 1 (Dose B) in Period 2.
  • Experimental: Cohort 2 - Treatment Sequence D
    Participant will receive a single dose of elecoglipron test formulation 1 (Dose B) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose B) in Period 2.
  • Experimental: Cohort 3 - Treatment Sequence E
    Participant will receive a single dose of elecoglipron reference formulation (Dose A) in Period 1 followed by a single dose of elecoglipron test formulation 2 (Dose A) in Period 2.
  • Experimental: Cohort 3 - Treatment Sequence F
    Participant will receive a single dose of elecoglipron test formulation 2 (Dose A) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose A) in Period 2.
  • Experimental: Cohort 4 - Treatment Sequence G
    Participant will receive a single dose of elecoglipron reference formulation (Dose B) in Period 1 followed by a single dose of elecoglipron test formulation 2 (Dose B) in Period 2.
  • Experimental: Cohort 4 - Treatment Sequence H
    Participant will receive a single dose of elecoglipron test formulation 2 (Dose B) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose B) in Period 2.

Primary Outcome Measure

Maximum observed drug concentration (Cmax) [ Time Frame: At pre-defined intervals from Day 1 to Day 15 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Research SiteGlendaleCalifornia91206-
Research SiteBrooklynMaryland21225-

Related Studies